- Home
- GMAB vs CYBR Comparison
GMAB vs CYBR Comparison
Compare GMAB & CYBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- CYBR
- Stock Information
- Founded
- GMAB 1999
- CYBR 1999
- Country
- GMAB Denmark
- CYBR Israel
- Employees
- GMAB N/A
- CYBR N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- CYBR Computer Software: Prepackaged Software
- Sector
- GMAB Health Care
- CYBR Technology
- Exchange
- GMAB Nasdaq
- CYBR Nasdaq
- Market Cap
- GMAB 15.0B
- CYBR 16.8B
- IPO Year
- GMAB N/A
- CYBR 2014
- Fundamental
- Price
- GMAB $21.80
- CYBR $355.58
- Analyst Decision
- GMAB Buy
- CYBR Strong Buy
- Analyst Count
- GMAB 8
- CYBR 30
- Target Price
- GMAB $43.00
- CYBR $353.87
- AVG Volume (30 Days)
- GMAB 1.1M
- CYBR 469.2K
- Earning Date
- GMAB 02-12-2025
- CYBR 02-13-2025
- Dividend Yield
- GMAB N/A
- CYBR N/A
- EPS Growth
- GMAB 14.35
- CYBR N/A
- EPS
- GMAB 10.80
- CYBR 0.29
- Revenue
- GMAB $2,967,926,227.00
- CYBR $909,462,000.00
- Revenue This Year
- GMAB $32.03
- CYBR $34.59
- Revenue Next Year
- GMAB $16.97
- CYBR $31.32
- P/E Ratio
- GMAB $19.02
- CYBR $1,391.97
- Revenue Growth
- GMAB 17.75
- CYBR 30.31
- 52 Week Low
- GMAB $19.85
- CYBR $223.09
- 52 Week High
- GMAB $31.88
- CYBR $363.00
- Technical
- Relative Strength Index (RSI)
- GMAB 54.72
- CYBR 67.95
- Support Level
- GMAB $19.89
- CYBR $331.64
- Resistance Level
- GMAB $21.26
- CYBR $363.00
- Average True Range (ATR)
- GMAB 0.42
- CYBR 10.37
- MACD
- GMAB 0.02
- CYBR 1.41
- Stochastic Oscillator
- GMAB 80.08
- CYBR 85.73
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About CYBR CyberArk Software Ltd.
CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader within that subsegment, with more than half of the Fortune 500 CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While historically, CyberArk has sold its security solutions primarily via on-premises licenses, over the past few years, it has transitioned to a subscription, recurring revenue model.